688331 荣昌生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)78.20725.367-54.148-35.907-23.706
总资产报酬率 ROA (%)54.54511.135-26.633-26.170-19.623
投入资产回报率 ROIC (%)62.08313.140-31.295-30.278-22.301

边际利润分析
销售毛利率 (%)95.71387.28080.36277.43264.766
营业利润率 (%)79.76122.227-84.786-138.651-128.900
息税前利润/营业总收入 (%)80.08123.845-81.479-140.043-138.154
净利润/营业总收入 (%)79.65221.828-85.526-139.547-129.364

收益指标分析
经营活动净收益/利润总额(%)92.8978.708102.862102.567112.858
价值变动净收益/利润总额(%)6.88789.5660.188-0.462-1.212
营业外收支净额/利润总额(%)-0.124-1.7180.8650.6420.359

偿债能力分析
流动比率 (X)4.8641.4291.0511.9763.663
速动比率 (X)4.3071.1910.7481.3183.067
资产负债率 (%)15.57050.21063.87837.82317.287
带息债务/全部投入资本 (%)4.62639.28854.41224.6532.168
股东权益/带息债务 (%)2,024.114149.57078.335295.1394,368.385
股东权益/负债合计 (%)542.27899.16456.550164.386478.465
利息保障倍数 (X)191.33811.958-20.133282.44815.718

营运能力分析
应收账款周转天数 (天)11.65244.63571.40583.05747.638
存货周转天数 (天)509.344574.923747.907931.109531.299